ArticleBMC microbiology2026
Genomic characteristics and drug resistance phenotype of Levyella massiliensis isolated from blood.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
This study reports the first isolation of a strain of Levyella massiliensis (strain HGL1) from human blood samples in China. Currently, the genomic characteristics, antibiotic resistance, and pathogenic potential of this species have not been fully studied. To systematically decipher the phylogenetic position, genomic composition, and potential pathogenicity-related factors of strain HGL1, this study employed a dual-platform sequencing strategy (PacBio Sequel II and Illumina NovaSeq PE150) for whole-genome sequencing of strain HGL1 and assessed its antibiotic susceptibility through antimicrobial susceptibility testing. Phylogenetic analysis revealed that strain HGL1 and L. massiliensis D22-N-7-79 reside within the same evolutionary clade, with an Average Nucleotide Identity (ANI) of 97.88% and a digital DNA-DNA hybridization (dDDH) value of 80%, supporting the classification of strain HGL1 as a member of L. massiliensis. Genomic analysis indicated that the HGL1 genome is 1,682,293 bp in size with a GC content of 48.85%, harboring a total of 1,613 predicted coding genes, 56 potential virulence genes, and 4 antibiotic resistance genes. Antimicrobial susceptibility testing results showed that this bacterium is susceptible to tigecycline, amoxicillin/clavulanic acid, and some β-lactam antibiotics; however, it exhibits resistance to macrolides (e.g., erythromycin, clarithromycin, azithromycin), trimethoprim/sulfamethoxazole, third-generation cephalosporins (ceftriaxone, cefotaxime), quinolones (ciprofloxacin, levofloxacin), and gentamicin. These findings demonstrate that L. massiliensis HGL1 is a bacterium possessing multidrug resistance and potential human pathogenicity. In-depth analysis of its genomic characteristics and resistance phenotype provides a scientific basis for understanding the biology and combating infections caused by this rare pathogen, underscoring the necessity for enhanced surveillance and research on this bacterium in future clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.